Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2018 | AML highlights from ASH 2018

Guillermo Garcia-Manero • 11 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Antibodies Checkpoint inhibitors Pracinostat Venetoclax

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, delivers key highlights, including exciting trials, future outlooks, and developments in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Guillermo Garcia-Manero

Potential strategies to prevent the evolution of CCUS to MDS
0:53
Potential strategies to prevent the evolution of CCUS to MDS
Guillermo Garcia-Manero • 7 Sep 2024
A total approach to MDS and unanswered questions in the field
2:38
A total approach to MDS and unanswered questions in the field
Guillermo Garcia-Manero • 7 Sep 2024
Key clinical trials in MDS taking place in the US
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
Sequencing of agents in LR-MDS
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Guillermo Garcia-Manero • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Guillermo Garcia-Manero • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Guillermo Garcia-Manero • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Guillermo Garcia-Manero • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals